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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The main objective is to assess the results at two years of ECP for OAG and primary angle closure in comparison to conventional
medical, laser, or surgical treatment, in terms of efficacy and safety. A secondary objective will be to examine the effect of the effects of
ECP treatment with concomitant phacoemulsification in comparison to ECP treatment alone.
B A C K G R O U N D
This protocol is based on the protocol from the published review
on ab interno trabecular bypass surgery with Trabectome for open
angle glaucoma (Hu 2016).
Description of the condition
Glaucoma is a progressive optic neuropathy, affecting 3.5% of
people aged 40 to 80 years (Tham 2014). It is the leading cause
of irreversible blindness, affecting over 64 million people globally
(Tham 2014). This figure is expected to increase to 110 million
people by 2040. Open angle glaucoma (OAG) is the common-
est type, accounting for 86% of cases (Tham 2014). In one large
population cohort, one in six people with OAG became bilat-
erally blind (Peters 2013). Angle closure glaucoma is less com-
mon than OAG, but is more likely to result in bilateral blind-
ness. The only proven way to prevent vision loss is to reduce the
pressure inside the eye (intraocular pressure (IOP)) over the long
term (AGIS 2000; CNTG Study Group 1998; Heijl 2002; Kass
2002). Approaches to reducing IOP include medical therapy, laser
treatments, and surgery. Because commercially available eye-drop
preparations have a short-lasting effect, medical therapy requires
eye-drops to be instilled one or more times daily for life. Adher-
ence is very poor, even if use is monitored (Friedman 2009; Okeke
2009). Conventional surgical techniques, such as trabeculectomy,
are associated with significant risks, with more than 40% of peo-
ple developing perioperative complications (Kirwan 2013; Lichter
2001) and reoperation being needed in 7% to 18% (Gedde 2012;
Kirwan 2013). Therefore, they are often reserved for disease that
is progressing despite other treatments (King 2013).
Description of the intervention
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In the past years, a number of minimally-invasive surgical tech-
niques have been developed with the aim of achieving long-term
reduction of IOP with a better safety profile than conventional
surgery (Francis 2011a). Among them, endoscopic cyclophoto-
coagulation (ECP) is a cyclodestructive procedure developed by
Martin Uram in 1992 (Uram 1995).
How the intervention might work
The ciliary body is the site of aqueous humour production. In
cyclodestructive procedures, the secretory epithelium of the cil-
iary epithelium is damaged, which leads to reduced aqueous hu-
mour secretion and lower IOP. Endoscopic cyclophotocoagula-
tion incorporates a diode laser, an aiming beam and video camera
imaging. Direct visualisation of the ciliary endothelium allows the
delivering of energy precisely to the ciliary processes in a highly
titratable fashion, while minimalizing collateral damage to the sur-
rounding tissue.
Why it is important to do this review
Consultationwith patients and healthcare professionals has identi-
fied a need for better treatments for glaucoma (James Lind Alliance
2013). Minimally-invasive glaucoma surgeries (MIGS) carry the
possibility of safe and effective long-term reduction of IOP, re-
moving concerns about permanent vision loss due to nonadher-
ence to eye-drops. A single treatment may also be more acceptable
to patients than daily and indefinite self-administration of eye-
drops. Initial results of ECPwere reported in 1992 byUram (Uram
1992), where he treated 10 eyes with neovascular glaucoma. Since
then, several studies have demonstrated the IOP-lowering effect
of ECP in different glaucoma forms (Chen 1997; Francis 2011b;
Lima 2004). In the light of the potential benefits for patients and
the widespread uptake of the technique, it is important to criti-
cally evaluate the evidence for the efficacy and safety of ECP treat-
ment. Importantly, ECP may be combined with phacoemulsifica-
tion (cataract surgery), a sight-restoring operation to remove the
natural lens of the eye when it has lost clarity. Since phacoemulsi-
fication itself reduces IOP (Mansberger 2012), we will specifically
examine the evidence for the efficacy of ECP when combined with
phacoemulsification in comparison to phacoemulsification alone.
This Cochrane review will be conducted in parallel with other
reviews currently undertaken by the Cochrane Eyes and Vision
MIGS Consortium, which includes minimally-invasive glaucoma
surgery (MIGS) techniques and devices such as the Trabectome
(NeoMedix, Tustin, California) (Hu 2016), Hydrus Schlemm’s
canal Microstent (Ivantis Inc., Irvine, California) (Otarola 2017),
XEN Glaucoma Implant (AqueSys Implant, Aliso Viejo, Califor-
nia) and IStent or IStent inject (Glaukos Corporation, Laguna
Hills, California).
O B J E C T I V E S
The main objective is to assess the results at two years of ECP for
OAG and primary angle closure in comparison to conventional
medical, laser, or surgical treatment, in terms of efficacy and safety.
A secondary objective will be to examine the effect of the effects
of ECP treatment with concomitant phacoemulsification in com-
parison to ECP treatment alone.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include randomised controlled trials (RCTs) only. We will
include reports of RCTs prepared in any language, irrespective of
their publication status.
Types of participants
Participants will have OAG of any type, including primary and
secondary OAG, or primary angle closure with raised IOP with
or without glaucoma (PAC-OHT or PACG). Secondary forms of
angle closure will be excluded. As there are no universally-accepted
criteria by which glaucoma may be defined, we will permit studies
to use their own definitions of glaucoma. In addition, participants
with ocular hypertension, normal tension glaucoma, or possible
glaucoma (suspects for glaucoma) will be included. We will not
apply any restrictions regarding location, setting, or demographic
factors.
Types of interventions
The intervention will be ECP. Although it is possible to deliver
variable degrees of treatment on the ciliary body with titratable
power levels, wewill not apply any particular inclusionor exclusion
criteria around these or other treatment delivery parameters. There
are two main approaches to reach ciliary body: via limbal or pars
plana entry. As the latter requires anterior vitrectomy, it cannot be
considered as MIGS, and will not be part of this review.
We will compare ECP to:
1. laser treatment (selective laser trabeculoplasty or argon laser
trabeculoplasty);
2. other MIGS techniques;
3. conventional glaucoma surgery (trabeculectomy)
4. medical therapy; or
5. in combination with phacoemulsification compared with
phacoemulsification alone (since phacoemulsification cataract
surgery is known to reduce IOP (Mansberger 2012)).
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Types of outcome measures
We will not use the reporting of particular outcomes as a criterion
for eligibility for review. We will not exclude studies from review
solely on the grounds of an outcome of interest not being reported.
Primary outcomes
The primary outcome will be the proportion of participants who
are drop-free (not using eye drops) at two years after randomisa-
tions.
Several different glaucoma outcome measures have been specified
as primary outcomes in other Cochrane Reviews and protocols
(Ismail 2015). A recent study classified IOP, visual field, safety,
and anatomic outcomes as being highly important to glaucoma
experts (Ismail 2016). A panel of patients from the Patient and
Public Involvement Group of the National Institute for Health
Research (NIHR) Biomedical Research Centre for Ophthalmol-
ogy identified drop-free disease control as a highly-valued outcome
(unpublished). We chose a participant-centred primary outcome.
In assessing this outcome, we will report how prescribing of IOP-
lowering eye drops was determined during follow-up. We will
examine whether the people measuring IOP and those deciding
upon the prescribing of IOP-lowering eye drops were masked to
treatment group.
Secondary outcomes
Secondary outcomes will be:
1. Mean change in IOP, measured using Goldmann
applanation tonometry, from randomisations to two years.
2. The proportions of participants experiencing intra- and
postoperative complications from randomisations to two-year
follow-up including but not restricted to the following:
◦ Loss of visual acuity (more than two Snellen lines or
more than 0.3 logMAR, according to the method of recording
visual acuity; or loss of light perception).
◦ Bleeding, as recorded by the investigators.
◦ Endophthalmitis, as recorded by the investigators.
◦ IOP spikes (postoperative rise in IOP, measured using
Goldmann applanation tonometry, of more than 10 mmHg
compared to the previous assessment, including during the first
postoperative month).
◦ Hypotony (significant postoperative reduction of IOP
to 6 mmHg or below).
◦ Phthisis bulbi, as recorded by the investigators.
◦ Secondary surgery, as recorded by the investigators.
3. Change from randomisations to two-year follow-up in
health-related quality of life measure.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search
the following electronic databases for randomised controlled trials
and controlled clinical trials. There will be no language or publi-
cation year restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which contains the Cochrane Eyes and Vision
Trials Register) in the Cochrane Library (latest issue) (Appendix
1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1980 to present) (Appendix 3);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch
(Appendix 4);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 5);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp)
(Appendix 6).
Searching other resources
We will search the reference lists of included studies for other
possible studies and will contact any individuals or organisations
whom we believe may have conducted or be conducting relevant
RCTs. We will also search the website of the manufacturer (Endo
Optiks, Little Silver, NJ, USA: endooptiks.com) for any informa-
tion on forthcoming trials.
Data collection and analysis
Selection of studies
Two review authors working independently will screen titles and
abstracts of all articles identified by the search using web-based
review management software (Covidence 2015). If abstracts are
not available, we will screen full-text articles. Two review authors
will independently assess full-text reports of all potentially eligible
studies. If there is disagreement regarding eligibility, a third review
author will arbitrate. If any full-text reports are rejected, we will
record the reasons for this.
Data extraction and management
We will extract data from reports of included studies using a data
collection form, which will be developed and piloted on the first
five studies included. Two review authors will work independently
to extract study characteristics from reports of each study and enter
the data into Review Manager 5 (RevMan 5) (Review Manager 5
2014). If there is disagreement, a third review author will arbitrate.
We will collect the following information on the characteristics of
included studies (Appendix 7):
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• Year of publication.
• Year of study.
• Country of study.
• Sample size.
• Participation rate.
• Method of recruitment.
• Eligibility criteria.
• Diagnostic criteria.
• Method of randomisations.
• Method of masking.
• Number of study arms.
• Types of participants.
• Types of interventions.
• Types of comparators.
• Use of phacoemulsification at the same time as the
intervention.
We will collect the following data regarding outcomes (Appendix
7):
• IOP at baseline.
• IOP at follow-up.
• Number of glaucoma medications at baseline.
• Number of glaucoma medications at follow-up.
• Intraoperative complications.
• Postoperative complications or secondary surgery.
• Duration of follow-up.
• Loss to follow-up.
• Intervals at which outcomes were assessed.
Where data on included studies are missing or unclear, we will
contact the individuals or organisations involved to obtain clari-
fication. We will collect and use the most detailed numerical data
available to facilitate analyses of included studies. We will attempt
to obtain these data from individuals or organisations in prefer-
ence to less precise methods such as extracting numeric data from
graphs. If this is necessary, two review authors will independently
extract the data and a third review author will arbitrate in case of
disagreement.
Assessment of risk of bias in included studies
We will use the latest version of the Cochrane ’Risk of bias’ tool
as described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) to assess the risk of bias
and assign judgements of this for included studies.
Measures of treatment effect
The primary outcome is the proportion of participants who are
drop-free two years after randomisations. We will use the risk ratio
as the measure of effect for this outcome.
We will report mean change in IOP from randomisations to two
years after randomisations. Secondary safety outcomes will be re-
ported as risk ratios. Health-related quality of life outcomes will
be reported as differences in means or risk ratios for continuous
and binary data, respectively.
Unit of analysis issues
We will assess whether included studies have included one or two
eyes from each participant and whether or not randomisations has
been conducted at the level of the participant or the eye. There is
a potential for medical treatments, such as topical beta blockers,
used for one eye to influence the outcome in the other eye (Piltz
2000). Surgery to lower IOP in one eye may also affect the IOP of
the fellow eye (Radcliffe 2010). Therefore, we will exclude studies
that have adopted a paired design.
Dealing with missing data
We will endeavour to minimize missing outcome data by contact-
ing individuals and organisations to obtain them. If the data are
unavailable, but the level ofmissing data in each group and reasons
for missing data in each group are similar, we may simply analyse
available case data if an intention-to-treat (ITT) analysis has not
been performed. If authors have conducted their own ITT analysis
despite missing data, we will document whether they provide any
justification for the method they have used to deal with missing
data and whether they have compared their ITT result with an
available case result.
Assessment of heterogeneity
We will assess the heterogeneity between trials by careful exami-
nation of the study reports, assessing forest plots, and an examina-
tion of the I2 value.We will consider I2 values greater than 50% as
indicative of substantial heterogeneity and, therefore, suggestive
that meta analysis might not be wise; however, we will give con-
sideration to the consistency of the effect estimates. If all estimates
are in the same direction, we might meta-analyse even where het-
erogeneity is evident; we will comment on the heterogeneity.
Assessment of reporting biases
We will use a funnel plot to assess the risk of publication bias if
there are more than 10 trials within our review.
Data synthesis
We will undertake a meta-analysis where data appear clinically,
methodologically, and statistically homogeneous. We will check
that participants, interventions, comparators, and outcomes are
sufficiently similar to give a clinically meaningful result and that
our I2 result indicates little inconsistency (i.e. I2 less than 50%).
If all estimates are in the same direction, we might meta-analyse
evenwhere heterogeneity is evident, but will comment on this.We
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will use a random-effects model unless there are fewer than three
eligible studies, in which case we will use a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
We will undertake a subgroup analysis. The effect modifier to be
examined will be use of phacoemulsification as a co-intervention.
Phacoemulsification has been shown to reduce IOP (Mansberger
2012).We will therefore analyse whether the effect of ECP surgery
differs depending on whether phacoemulsification is used as a co-
intervention.
Sensitivity analysis
We will assess the impact of including studies at high risk of bias
for an outcome in one or more key domains.
Summary of findings
We will prepare tables to summarise the findings of the review,
including the assessment of the quality of evidence for all outcomes
using the GRADE approach (GRADEpro 2014). All outcomes
considered in the review will be reported in the summary.
We will report the following outcomes in the ’Summary of find-
ings’ table and the comparison groups described under Types
of interventions: ECP compared with laser treatment, other
MIGS techniques, conventional glaucoma surgery (trabeculec-
tomy), medical therapy or in combination with phacoemulsifica-
tion compared with phacoemulsification alone.
1. Proportion of participants who are drop-free (not using eye
drops) at two years follow-up.
2. Mean change in number of IOP-lowering drops taken per
day from baseline to two years follow-up.
3. Mean change in IOP, measured using Goldmann
applanation tonometry, from baseline to two years follow-up.
4. Health-related quality of life at two years follow-up.
5. Intraoperative complications.
6. Postoperative complications up to two years follow-up.
7. Secondary glaucoma surgery, including laser, as recorded by
the investigators of the included trials between baseline and two
years follow-up.
A C K N OW L E D G E M E N T S
Cochrane Eyes and Vision (CEV) will create and execute the elec-
tronic search strategies. We thank Nitin Anand and Jennifer Evans
for their comments on the published protocol that forms the tem-
plate for this one (Hu 2016) and Anupa Shah for assisting with
the review process.
We thank the members of the MIGS Consortium for their input
in this protocol.
R E F E R E N C E S
Additional references
AGIS 2000
AGIS Investigators. The Advanced Glaucoma Intervention
Study (AGIS): 7. The relationship between control of
intraocular pressure and visual field deterioration. American
Journal of Ophthalmology 2000;130(4):429–40.
Chen 1997
Chen J, Cohn RA, Lin SC, Cortes AE, Alvarado JA.
Endoscopic photocoagulation of the ciliary body for
treatment of refractory glaucomas. American Journal of
Ophthalmology 1997;124(6):787–96.
CNTG Study Group 1998
Collaborative Normal-Tension Glaucoma Study Group.
Comparison of glaucomatous progression between
untreated patients with normal-tension glaucoma and
patients with therapeutically reduced intraocular pressures.
American Journal of Ophthalmology 1998;126(4):487–97.
Covidence 2015 [Computer program]
Veritas Health Innovation. Covidence. Version accessed
prior to 25 April 2017. Melbourne: Veritas Health
Innovation, 2015.
Francis 2011a
Francis BA, Singh K, Lin SC, Hodapp E, Jampel HD,
Samples JR, et al. Novel glaucoma procedures: a report by
the American Academy of Ophthalmology. Ophthalmology
2011;118(7):1466–80.
Francis 2011b
Francis BA, Kawji AS, Vo NT, Dustin L, Chopra
V. Endoscopic cyclophotocoagulation (ECP) in the
management of uncontrolled glaucoma with prior aqueous
tube shunt. Journal of Glaucoma 2011;20(8):523-7.
Friedman 2009
Friedman DS, Okeke CO, Jampel HD, Ying GS, Plyler RJ,
Jiang Y, et al. Risk factors for poor adherence to eyedrops
in electronically monitored patients with glaucoma.
Ophthalmology 2009;116(6):1097–105.
Gedde 2012
Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ,
Schiffman JC, et al. Postoperative complications in the
Tube Versus Trabeculectomy (TVT) study during five years
of follow-up. American Journal of Ophthalmology 2012;153
(5):804–14.
5Endoscopic cyclophotocoagulation (ECP) for open angle glaucoma and primary angle closure (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Glanville 2006
Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J.
How to identify randomized controlled trials in MEDLINE:
ten years on. Journal of the Medical Library Association 2006;
94(2):130–6.
GRADEpro 2014 [Computer program]
GRADE Working Group, McMaster University.
GRADEpro GDT. Version accessed prior to 25 April 2017.
Hamilton (ON): GRADE Working Group, McMaster
University, 2014.
Heijl 2002
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson
B, Hussein M, et al. Reduction of intraocular pressure
and glaucoma progression: results from the Early Manifest
Glaucoma Trial. Archives of Ophthalmology 2002;120(10):
1268–79.
Higgins 2011
Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8:
Assessing risk of bias in included studies. In: Higgins JP,
Green S, editor(s). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Hu 2016
Hu K, Gazzard G, Bunce C, Wormald R. Ab interno
trabecular bypass surgery with Trabectome for open angle
glaucoma. Cochrane Database of Systematic Reviews 2016,
Issue 8. [DOI: 10.1002/14651858.CD011693.pub2]
Ismail 2015
Ismail R, Azuara-Blanco A, Ramsay CR. Outcome measures
in glaucoma: a systematic review of Cochrane reviews and
protocols. Journal of Glaucoma 2015;24(7):533–8.
Ismail 2016
Ismail R, Azuara-Blanco A, Ramsay CR. Consensus on
outcome measures for glaucoma effectiveness trials: results
from a delphi and nominal group technique approaches.
Journal of Glaucoma 2016;25(6):539–46.
James Lind Alliance 2013
James Lind Alliance Sight Loss, Vision Priority
Setting Partnership. Setting priorities for eye research.
www.sightlosspsp.org.uk (accessed 5 June 2017).
Kass 2002
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA,
Keltner JL, Miller JP, et al. The Ocular Hypertension
Treatment Study: a randomized trial determines that topical
ocular hypotensive medication delays or prevents the onset
of primary open-angle glaucoma. Archives of Ophthalmology
2002;120(6):701–13.
King 2013
King A, Azuara-Blanco A, Tuulonen A. Glaucoma. BMJ
2013;346:f3518.
Kirwan 2013
Kirwan JF, Lockwood AJ, Shah P, Macleod A, Broadway
DC, King AJ, et al. Trabeculectomy in the 21st century: a
multicenter analysis. Ophthalmology 2013;120(12):2532–9.
Lichter 2001
Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz
NK, Wren PA, et al. Interim clinical outcomes in the
Collaborative Initial Glaucoma Treatment Study comparing
initial treatment randomized to medications or surgery.
Ophthalmology 2001;108(11):1943–53.
Lima 2004
Lima FE, Magacho L, Carvalho DM, Susanna R Jr, Avila
MP. A prospective, comparative study between endoscopic
cyclophotocoagulation and the Ahmed drainage implant
in refractory glaucoma. Journal of Glaucoma 2004;13(3):
233–7.
Mansberger 2012
Mansberger SL, GordonMO, Jampel H, Bhorade A, Brandt
JD, Wilson B, et al. Reduction in intraocular pressure after
cataract extraction: the Ocular Hypertension Treatment
Study. Ophthalmology 2012;119(9):1826–31.
Okeke 2009
Okeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ,
Jiang Y, et al. Adherence with topical glaucoma medication
monitored electronically. The Travatan Dosing Aid study.
Ophthalmology 2009;116(2):191–9.
Otarola 2017
Otarola F, Hu K, Gazzard G, Bunce C. Ab interno trabecular
bypass surgery with Schlemm´ s Canal Microstent
(Hydrus) for open angle glaucoma. Cochrane Database
of Systematic Reviews 2017, Issue 8. [DOI: 10.1002/
14651858.CD012740]
Peters 2013
Peters D, Bengtsson B, Heijl A. Lifetime risk of blindness in
open-angle glaucoma. American Journal of Ophthalmology
2013;156(4):724–30.
Piltz 2000
Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, et
al. Contralateral effect of topical beta-adrenergic antagonists
in initial one-eyed trials in the ocular hypertension
treatment study. American Journal of Ophthalmology 2000;
130(4):441–53.
Radcliffe 2010
Radcliffe NM, Musch DC, Niziol LM, Liebmann JM, Ritch
R, Collaborative Initial Glaucoma Treatment Study Group.
The effect of trabeculectomy on intraocular pressure of the
untreated fellow eye in the collaborative initial glaucoma
treatment study. Ophthalmology 2010;117(11):2055–60.
Review Manager 5 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Tham 2014
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng
CY. Global prevalence of glaucoma and projections of
glaucoma burden through 2040: a systematic review and
meta-analysis. Ophthalmology 2014;121(11):2081–90.
6Endoscopic cyclophotocoagulation (ECP) for open angle glaucoma and primary angle closure (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Uram 1992
Uram M. Ophthalmic laser microendoscope ciliary process
ablation in the management of neovascular glaucoma.
Ophthalmology 1992;99(12):1823–8.
Uram 1995
Uram M. Endoscopic cyclophotocoagulation in glaucoma
management. Current Opinion in Ophthalmology 1995;6
(2):19–29.
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Glaucoma, Open-Angle] explode all trees
#2 MeSH descriptor: [Intraocular Pressure] explode all trees
#3 MeSH descriptor: [Ocular Hypertension] explode all trees
#4 OAG or POAG or IOP or OHT
#5 simple near/3 glaucoma*
#6 open near/2 angle near/2 glaucoma*
#7 chronic near/2 glaucoma*
#8 secondary near/2 glaucoma*
#9 low near/2 tension near/2 glaucoma*
#10 low near/2 pressure near/2 glaucoma*
#11 normal near/2 tension near/2 glaucoma*
#12 normal near/2 pressure near/2 glaucoma*
#13 pigment near/2 glaucoma*
#14 MeSH descriptor: [Exfoliation Syndrome] this term only
#15 exfoliat* near/2 syndrome*
#16 exfoliat* near/2 glaucoma*
#17 pseudoexfoliat* near/2 syndrome*
#18 pseudoexfoliat* near/2 glaucoma*
#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 endoscop* near/2 cyclophotocoagulat*
#21 ECP
#22 #20 or #21
#23 #19 and #22
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Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp glaucoma open angle/
14. exp intraocular pressure/
15. ocular hypertension/
16. (OAG or POAG or IOP or OHT).tw.
17. (simple$ adj3 glaucoma$).tw.
18. (open adj2 angle adj2 glaucoma$).tw.
19. (primary adj2 glaucoma$).tw.
20. (chronic adj2 glaucoma$).tw.
21. (secondary adj2 glaucoma$).tw.
22. (low adj2 tension adj2 glaucoma$).tw.
23. (low adj2 pressure adj2 glaucoma$).tw.
24. (normal adj2 tension adj2 glaucoma$).tw.
25. (normal adj2 pressure adj2 glaucoma$).tw.
26. (pigment$ adj2 glaucoma$).tw.
27. exfoliation syndrome/
28. (exfoliat$ adj2 syndrome$).tw.
29. (exfoliat$ adj2 glaucoma$).tw.
30. (pseudoexfoliat$ adj2 syndrome$).tw.
31. (pseudoexfoliat$ adj2 glaucoma$).tw.
32. or/13-31
33. (endoscop$ adj2 cyclophotocoagulat$).tw.
34. ECP.tw.
35. 33 or 34
36. 32 and 35
37. 12 and 36
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. EMBASE Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
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11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. open angle glaucoma/
34. intraocular pressure/
35. intraocular hypertension/
36. (OAG or POAG or IOP or OHT).tw.
37. (open adj2 angle adj2 glaucoma$).tw.
38. (primary adj2 glaucoma$).tw.
39. (chronic adj2 glaucoma$).tw.
40. (secondary adj2 glaucoma$).tw.
41. (low adj2 tension adj2 glaucoma$).tw.
42. (low adj2 pressure adj2 glaucoma$).tw.
43. (normal adj2 tension adj2 glaucoma$).tw.
44. (normal adj2 pressure adj2 glaucoma$).tw.
45. (pigment$ adj2 glaucoma$).tw.
46. exfoliation syndrome/
47. (exfoliat$ adj2 syndrome$).tw.
48. (exfoliat$ adj2 glaucoma$).tw.
49. (pseudoexfoliat$ adj2 syndrome$).tw.
50. (pseudoexfoliat$ adj2 glaucoma$).tw.
51. or/33-50
52. (endoscop$ adj2 cyclophotocoagulat$).tw.
53. ECP.tw.
54. 52 or 53
55. 51 and 54
56. 32 and 55
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Appendix 4. ISRCTN search strategy
endoscopic cyclophotocoagulation OR ECP
Appendix 5. ClinicalTrials.gov search strategy
endoscopic cyclophotocoagulation
Appendix 6. ICTRP search strategy
endoscopic cyclophotocoagulation
Appendix 7. Data on study characteristics
Mandatory items Optional items
Methods
Study design ·Parallel group RCT i.e. people randomised
to treatment
· Within-person RCT i.e. eyes randomised
to treatment
· Cluster RCT i.e. communities randomised
to treatment
· Cross-over RCT
· Other, specify
Number of study arms
Method of randomisation
Exclusions after randomisation
Losses to follow-up
Number randomised/analysed
Method of masking
How were missing data handled? e.g. avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes
Unit of randomisation/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture of one eye and two
eyes
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-
rect pair-matched analysis done
Participants
Country Setting
Ethnic group
Method of recruitment
Participation rate
Equivalence of baseline characteristics (Y/
N)
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(Continued)
Diagnostic criteria
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are reported for the people whowere
followed up only, please indicate.
Number (%) of men and women Number (%) of men and women
Average age and age range Average age and age range
Inclusion criteria -
Exclusion criteria -
Interventions
Intervention (n = )
Comparator (n = )
· Number of people randomised to this
group
· Intervention name
· Comparator name
· Specify whether phacoemulsification, or
other intervention, performed at same time
as intervention
ECP surgical parameters, e.g. degrees of cil-
iary epithelium treated, laser power
Comparator parameters, e.g. dosage of drugs
Outcomes
Primary and secondary outcomes as defined
in study reports
· IOP at baseline
· IOP at follow-up
·Number of glaucomamedications at base-
line
· Number of glaucoma medications at fol-
low-up
· Intraoperative complications
· Postoperative complications or secondary
surgery
· Duration of follow-up
· Loss to follow-up
· Intervals at which outcomes assessed
Adverse events reported (Y/N)
Planned/actual length of follow-up
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Date of publication
Reported subgroup analyses (Y/N)
Were trial investigators contacted?Sources of funding
Declaration of interest
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External sources
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